Aktis Oncology, Inc. Cash and Restricted Cash
Aktis Oncology, Inc. (AKTS) had Cash and Restricted Cash of $83.64 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $83.64M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $372.78M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38.93M.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $111.36M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $83.64M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $372.78M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $38.93M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $111.36M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $59.40M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $38.31M 10-Q · filed 2026-08-13 |